Health
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-deve...
2019-06-04 08:00
10242
Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of circulating tumor DNA (ctDNA) for predicting response and resistance ...
2019-06-04 08:00
3466
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 4, 2019 /PRNewswire/ -- * Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis * N...
2019-06-04 02:16
3066
IMG Announces Start of Annual Leave Your Mark Essay Contest
INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning, global insurance benefits and assistance services company is pleased to announce the start of their third annual Leave Your Mark essay contest, designed to benefit mission organizations around the wo...
2019-06-04 01:02
2027
Frost & Sullivan Publishes Q1 Update on Kadimastem
Continues its plans as expected; Ministry of Health approval for central experiment; financing is required to continue operations at the beginning of 2020; received Orphan Drug Designation from the FDA; target price unchanged. TEL AVIV, Israel, June 3, 2019 /PRNewswire/ -- The TASE analysis proje...
2019-06-03 21:24
1636
Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology
- First field trial achieved up to 96% suppression of target disease-transmitting mosquito populations in dense urban settings inBrazil - Results indicate an increase in cost effectiveness over the 1st Generation with limited production requirements CAMPINAS, Brazil, June 3, 2019 /PRNewswire/ -...
2019-06-03 20:30
7022
International Medical Innovation and Cooperation Forum held in Fangchenggang City
FANGCHENGGANG, China, June 3, 2019 /PRNewswire/ -- As reported by CRI Online: Recently, the International Medical Innovation and Cooperation Forum (China-Shanghai Cooperation Organization), co-sponsored by the Shanghai Cooperation Organization Good-Neighborly Friendship and Cooperation Committee ...
2019-06-03 19:43
3627
Chung Yuan Christian University plans to lead delegation of Taiwanese startups eyeing Australian market
TAIPEI, , June 3, 2019 /PRNewswire/ -- The Innovation & Incubation Center (IAIC), an arm of the Executive Operation Office for Industry-Academia Cooperation at Chung Yuan Christian University (CYCU) hosted the International Venture Capital Investment Match event onMay 27, 2019. Over 10 internatio...
2019-06-03 10:24
5085
Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...
2019-06-03 08:00
3239
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences
SUZHOU, China, June 3, 2019 /PRNewswire/ -- The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (ChiCTR-OIC-17013726), led by ProfessorJie He, Dean of the Cancer Hospital of the Chinese Academy of ...
2019-06-03 08:00
11746
Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified
HONG KONG, June 1, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced that the Group has completed the post-launch clinical trials of "Cinepazide Maleate Inject...
2019-06-01 11:18
1902
Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer
SUZHOU, China, May 31, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of sintilimab, the anti-PD-1 antibody that co-developed with...
2019-05-31 08:00
4219
New NCCN Guidelines for Children with Cancer Meet Growing Needs of Pediatric Oncology Community Worldwide
New NCCN Guidelines® for Pediatric ALL include a strong focus on supportive care in order to reduce dangerous side-effects in children undergoing treatment for acute lymphoblastic leukemia, and share best practices for emerging treatments like immunotherapy, CAR T-cells, and targeted therapies. ...
2019-05-30 21:30
2310
Anpac Bio Presenting 'Unprecedented' Cerebral Cancer Liquid Biopsy Research Results at ASCO 2019
SACRAMENTO, California, May 30, 2019 /PRNewswire/ -- International life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio) Chief Executive Officer Dr.Chris Yu, announced today the company is presenting "unprecedented" cerebral cancer research results at theAmerican Society of Cl...
2019-05-30 20:00
3495
TUV Rheinland Certifies Dell Notebooks with Eyesafe(R) Display for Low Blue Light Requirements
TAIPEI, , May 30, 2019 /PRNewswire/ -- TUV Rheinland
2019-05-30 19:45
6246
Enterprise Content Management Market Doubles in Size with Healthcare Digitization
Rapid proliferation of disparate clinical and non-clinical information systems in care settings is creating growth opportunities, finds Frost & Sullivan SANTA CLARA, California, May 30, 2019 /PRNewswire/ -- Healthcare organizations' urgent need to digitally consolidate administrative, operationa...
2019-05-30 18:01
2108
Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA
SHANGHAI, May 30, 2019 /PRNewswire/ -- Rykindo® (LY03004), Luye Pharma's innovative, independently developed Extended-Release Microspheres formulation for injection, is one step closer to going on the U.S. market. The US Food and Drug Administration (FDA) has completed the filing review and acce...
2019-05-30 13:09
2663
CPhI & P-MEC China to have grand opening in June in Shanghai
SHANGHAI, May 30, 2019 /PRNewswire/ -- On June 18-20, 2019, as the indicator of the pharmaceutical expo, the 19th International Exhibition on Chemical Pharmaceutical Ingredient China (CPhI China) sponsored byChina Chamber of Commerce of Medicines & Health Products Importers & Exporters and Inform...
2019-05-30 11:02
2015
Johnson & Johnson Malaysia champions the importance of mental health this Ramadhan
KUALA LUMPUR, Malaysia, May 30, 2019 /PRNewswire/ -- Mental health is fast becoming a national concern. By 2020, one in three Malaysians are expected to suffer some form of mental health problem[1]. Seeing this, Johnson & Johnson Malaysia, in collaboration with the Mental Illness Awareness and ...
2019-05-30 09:00
5240
PHS Health Solutions Unveils Company Rebrand to Amplity Health
New Brand Identity Sets the Stage for a New Pure-play Commercialization Partner to the Pharmaceutical Industry YARDLEY, Pennsylvania, May 29, 2019 /PRNewswire/ -- PHS Health Solutions (PHS), a leading pharmaceutical contract commercial organization with an exemplary 35-year track record as ...
2019-05-29 22:00
1696
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 318 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 316 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 309 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 295 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
15085
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
10426
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9812
